Related Experiment Video
Updated: May 9, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Pramipexole and its extended release formulation for Parkinson's disease
1Department of Neurology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Journal of Central Nervous System Disease
|July 18, 2013
Summary
Extended-release pramipexole offers improved compliance for Parkinson's disease patients. This new formulation demonstrates comparable efficacy and safety to the immediate-release version, with potential benefits in managing motor fluctuations.
Area of Science:
- Neurology
- Pharmacology
Background:
- Pramipexole is a well-established dopamine agonist for Parkinson's disease (PD).
- An extended-release (ER) formulation of pramipexole is now available for early and advanced PD.
- ER formulations may offer advantages in patient compliance and symptom management.
Purpose of the Study:
- To evaluate the efficacy and safety of extended-release pramipexole.
- To compare ER pramipexole with placebo and immediate-release (IR) pramipexole.
- To assess ER pramipexole as monotherapy and adjunct therapy in Parkinson's disease.
Main Methods:
- Randomized, multicenter clinical trials were conducted.
- Patients with early PD received ER pramipexole as monotherapy.
- Patients with advanced PD and motor fluctuations on Levodopa (L-DOPA) received ER pramipexole as adjunct therapy.
Main Results:
- ER pramipexole showed superior efficacy to placebo in both early and advanced PD.
- ER pramipexole demonstrated comparable efficacy to IR pramipexole.
- The side effect profile was similar between ER and IR pramipexole, including nausea, sleepiness, edema, dyskinesias, hallucinations, and impulse control disorders.
Conclusions:
- Extended-release pramipexole is an effective treatment option for Parkinson's disease.
- ER pramipexole offers comparable efficacy to the immediate-release formulation with improved dosing convenience.
- The safety profile of ER pramipexole is similar to the IR formulation.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...